#neurological biomarkers

[emed123]

Recent Insights in Alzheimer Research |

Discover the latest insights into Alzheimers research, shedding light on advancements in diagnosis and treatment.

[businesspointnews]

Neurological Biomarkers Market Size, Demand, Share, Growth and Forecast 2023-2028

IMARC Group has recently released a new research study titled “Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios. How Big is the Neurological Biomarkers…

[blogaarti]

Neurological Biomarkers Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2029

There have been significant advancements in neurological science and medical understanding of the field. Many previously untreatable neurological disorders now have efficacious treatments and therapeutics to sustain the healthy lifestyle of the patients. Significant grounds are being made in understanding the pathomechanism of neurological disorders and the ability to diagnose and treat them effectively. Developing a better understanding of neurological biomarkers is one of the key factors behind such promising developments. Combined with growing neurosurgical advancements, medical professionals can utilise these insights to improve surgical procedures. As per some estimates, over 13.8 million people require neurological surgery to treat illnesses and trauma every year. Moreover, the growing incidence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and autism spectrum disorder is incenting the developments in neuroscience, thereby promoting the growth of the global neurological biomarkers market.  

 For More Industry Insights Read: https://www.fairfieldmarketresearch.com/report/neurological-biomarkers-market

Medical Tech Advancements to Open New Avenues of Growth 

In the recent past, the advancements in neurological diagnostics and treatment have showcased tremendous technological advancements. This is a necessity as the prevalence of neurological disorders has been growing incessantly in the past few decades. Such alarming trends are creating a need for novel biomarker identification methods for neurological disorders. In addition, these digital biomarkers are being used for clinical trials and analytical epidemiology for better disease management and prevention. There is a significant increase in the usage of neurological biomarkers to analyse pathological processes and the expansion of biobanks for optimal healthcare delivery. These factors are poised to drive the growth of the global neurological biomarkers market during the forecast years.

Growing Adoption of Neurosurgery to Create Significant Opportunity in Neurological Biomarkers Market

Healthcare technological advancements are enabling several positive changes in the healthcare industry. Positive trends can be observed in surgical equipment development and increased neurological healthcare awareness. In addition, robust research and development in the field are collectively sustaining sound market growth. The demand for neurosurgeries has been growing at a considerable pace in the past few years. In addition, the modern restless lifestyle is catalysing the cases of overfeeding, sleep deprivation, sedentary lifestyle, and social isolation. These factors have significantly proliferated the cases of depression across the globe. The efforts to overcome such neurological healthcare challenges are expected to create growth possibilities in the global neurological biomarkers market.

North America to Maintain Market Leadership Amidst Paced Neurological Diagnostics and Therapeutics Innovations 

In North America, the neurological illness burden is high and the adoption of biomarkers in therapeutic development is growing. These factors are facilitating the growth of the regional neurological biomarkers market. The region homes several key market players and has favourable government and regulatory support for medical science advancements. The adoption of neuropathy in regional economies such as the USA is increasing, thereby maintaining North America’s market leadership status. Meanwhile, Asia Pacific is expected to be the fastest-growing neurological biomarkers market. This is due to the growing number of clinical trials undergoing in economies such as China and India.

Notable Market Entities 

Some of the key players in the global neurological biomarkers market include Abbott, Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., BANYAN BIOMARKERS, INC., Thermo Fisher Scientific, Inc., Myriad Genetics, Inc., Merck & Co. Inc., DiaGenic ASA, and Quanterix.

 For More Information Visit: https://www.fairfieldmarketresearch.com/report/neurological-biomarkers-market

 About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[twitchywoman]

A Breakthrough from the Michael J Fox Foundation!

[longhaulerbear]

Our study identified 119 proteins that differentiated Long-COVID outpatients from acutely ill COVID-19 inpatients and healthy control subjects. Each of the 119 proteins was significantly different in Long-COVID outpatients, as compared to other cohorts.

Two optimal models, with a subset of nine and five proteins, accurately differentiated Long-COVID patients from acutely ill COVID-19 inpatients and healthy control subjects.

The first optimal model contained nine proteins: CXCL5, AP3S2, MAX, PDLIM7, FRZB, EDAR, LTA4H, CRACR2A, and CXCL3. The optimal second model is a subset of the first with five proteins: CXCL5, AP3S2, MAX, PDLIM7, and FRZB.

The functions of the optimal nine proteins varied widely and appropriately corroborated that Long-COVID is a multifaceted condition in which multiple systems are affected.

The digestive system had the highest number of significant proteins with altered expression. This finding was consistent with a significant gut biome change identified in Long-COVID patients when compared to both controls and recovered COVID-19 patients without Long-COVID symptoms.

CES3 played an important role in adipocyte differentiation and promoted lipid storage.

Overexpression of SRC is involved with colon cancer and often results in metastasis via its signalling pathways.

The lymphatic system appeared to be highly affected in Long-COVID as more than 50% of the 60 significant proteins had expression in lymphatic organs. Of the 44 proteins with cell type expression information, lymphocytes and leukocytes not yet determined were the two most common cell types. Consistent with protein expression, autopsies of critically ill COVID-19 patients have revealed changes to the structure of the spleen and lymph nodes.

CRACR2A and CXCL3 were both linked to immune cell activation and may indicate an ongoing immune response in Long-COVID outpatients. CRACR2A participated in T-cell activation and functional CRACR2A changes were linked to immunodeficiency disorders.

Long-COVID appeared to highly impact the nervous system with symptoms often including headaches, fatigue, and brain fog (Raveendran et al. 2021; Ortelli, et al. 2021). The NLP expression analysis showed that a large number of proteins are highly expressed in the nervous system, particularly in neurons. FRZB, AP3S2, and MAX were not only part of the optimal model, but were also linked to neurological conditions. FRZB was linked to defects in sensory innervation and spinal innervation (John et al. 2012), and decreased FRZB expression was associated with increased neuronal development (Jang et al. 2013). AP3S2 was a small chain of the Adaptor-related protein complex 3 (AP-3). AP-3 subunit defects lead to severe neurological abnormalities including neurodevelopmental delays, intellectual disability and seizures (Guardia et al. 2018). MAX mutations were associated with hereditary pheochromocytoma, a neural crest cell-based neuroendocrine tumour in the adrenal medulla.

Beyond the panel of optimal proteins, PLXNB3, APP, and BDNF were also associated with neurological conditions. PLXNB3, overexpressed in our Long-COVID outpatients has been previously linked to COVID-19 (Yaşar et al. 2021); it was shown to stimulate neurite outgrowth in mice and was also associated with verbal performance and brain white matter volume in humans (Hartwig et al. 2005; Rujescu et al. 2007). Overexpression of APP was either a protective response leading to cell health and growth, or detrimental with increased Aß accumulation and decreased dendritic synapses (Hoe et al. 2012; O'Brien and Wong 2011). BDNF upregulation was shown to increase proliferation and differentiation of neural stem cells.

Survivors of acute COVID-19 were at an increased risk of developing cardiovascular disorders including ischemic heart disease, inflammatory heart disease, dysrhythmias, and thrombotic disorders (Xie et al. 2022). Vascular endothelial injury, angiogenesis and thrombosis were associated with acute COVID-19 pathophysiology.

Several pro-coagulation factors were in the top 119 proteins including GP5, GP6, and STX8 (Moog et al. 2001; Golebiewska et al. 2015). GP5 and GP6 are involved in platelet adhesion and aggregation (Moog et al. 2001; Veninga et al. 2022) and STX8 is involved in platelet granule secretion, aggregation and thrombus stability.

CCL17 was also noted to be an important biomarker for eosinophilic disorders including differentiating eosinophilic pneumonia from acute lung injury.

Overexpression of EREG, GTPBP2, and DRG2 was linked to tumor growth in non-small cell lung cancer.

[visionresearchreports]

The global Neurological Biomarkers market size is estimated to be worth US$ 6937 million in 2021 and is forecast to a readjusted size of US$ 15480 million by 2030 with a CAGR of 12.0% during the forecast period 2022-2030.

[reasonsforhope]

Researchers from Western and Brown University have made groundbreaking progress towards identifying the root cause and potential therapy for preeclampsia.

The pregnancy complication affects up to eight per cent of pregnancies globally and is the leading cause of maternal and fetal mortality due to premature delivery, complications with the placenta and lack of oxygen.

The research, led by Drs. Kun Ping Lu and Xiao Zhen Zhou at Western, and Drs. Surendra Sharma and Sukanta Jash at Brown, has identified a toxic protein, cis P-tau, in the blood and placenta of preeclampsia patients.

According to the study published in Nature Communications, cis P-tau is a central circulating driver of preeclampsia – a “troublemaker” that plays a major role in causing the deadly complication...

“The root cause of preeclampsia has (so far) remained unknown, and without a known cause there has been no cure. Preterm delivery is the only life-saving measure,” said Lu, professor of biochemistry and oncology at  Schulich School of Medicine & Dentistry...

“Our study identifies cis P-tau as a crucial culprit and biomarker for preeclampsia. It can be used for early diagnosis of the complication and is a crucial therapeutic target,” said Sharma...

Until now, cis P-tau was mainly associated with neurological disorders like Alzheimer’s disease, traumatic brain injuries (TBI) and stroke. This association was discovered by Lu and Zhou in 2015 as a result of their decades of research on the role of tau protein in cancer and Alzheimer’s.

An antibody developed by Zhou in 2012 to target only the toxic protein while leaving its healthy counterpart unscathed is currently undergoing clinical trials in human patients suffering from TBI and Alzheimer’s Disease. The antibody has shown promising results in animal models and human cell cultures in treating the brain conditions.

The researchers were curious whether the same antibody could work as a potential treatment for preeclampsia. Upon testing the antibody in mouse models they found astonishing results.

“In this study, we found the cis P-tau antibody efficiently depleted the toxic protein in the blood and placenta, and corrected all features associated with preeclampsia in mice. Clinical features of preeclampsia, like elevated blood pressure, excessive protein in urine and fetal growth restriction, among others, were eliminated and pregnancy was normal,” said Sharma.

Sharma and his team at Brown have been working on developing an assay for early detection of preeclampsia and therapies to treat the condition. He believes the findings of this study have brought them closer to their goal...

“The results have far-reaching implications. This could revolutionize how we understand and treat a range of conditions, from pregnancy-related issues to brain disorders,” said Lu.

-via India Education Diary, September 22, 2023

[tieflingkisser]

Brain Damage Detected in Many COVID-19 Patients

The impact of the COVID-19 pandemic persists beyond the declared health emergency, with new research indicating potential long-term effects on patients, including brain damage. A preprint study sheds light on the aftermath of the coronavirus, suggesting that COVID-19 may lead to silent organ damage, particularly in the brain. Ongoing studies have focused on the neurological effects of COVID-19, prompted by reports from individuals experiencing prolonged symptoms, known as Long Covid, including memory and concentration issues. The colloquially termed "brain fog" has raised concerns about potential long-term brain damage and its correlation with the early development of dementia, as revealed in a preprint study. Recent research conducted in the United Kingdom has delved into the connection between COVID-19 and brain damage. Led by neuroscientist Benedict Michael, a research team examined the cognitive performance of 351 hospitalized COVID-19 patients in a national longitudinal study. Utilizing cognitive tests, blood samples to identify biomarkers indicative of brain damage, and brain scans, the researchers identified notable damage to the patients' brains. This preprint study, currently undergoing peer review, suggests that the observed brain damage corresponds to an accelerated aging of the brain by approximately 20 years. The preliminary version of the study notes, "Compared to normative age-matched data, these deficits corresponded in magnitude to aging between the ages of 50 and 70." While cognitive impairments were detected in all patients, the study does not conclusively determine whether the brain damage leads to permanent cognitive decline, leaving this aspect open to further investigation.

[businesspointnews]

Neurological Biomarkers Market Share, Growth Factors, Trends, Segmentation and Forecast Analysis Till 2032

How big is the neurological biomarkers market? The global neurological biomarkers market size reached US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032. Neurological Biomarkers: What & Uses: Neurological biomarkers refer to the biomarkers that are considered standards for…